Advertisement

Editorial

Published:January 14, 2017DOI:https://doi.org/10.1016/j.xphs.2017.01.011
      On January 1, 2014, I appointed 73 eminent scientists for 3-year terms on the Journal of Pharmaceutical Sciences (JPharmSci®) Editorial Advisory Board (EAB). The terms of these individuals will expire on December 31, 2016. I am pleased to announce here that the following individuals have accepted reappointments to the JPharmSci® EAB for another 3-year term (January 1, 2017-December 31, 2019): Gregory E. Amidon, University of Michigan; Tom J. Anchordoquy, University of Colorado; Per Artursson, Uppsala University; Patrick Augustijns, KU Leuven; Bruce J. Aungst, AUC Sciences; Joseph P. Balthasar, SUNY Buffalo; Sathy Balu-Iyer, SUNY Buffalo; James G. Bann, Wichita State University; Michael Blaber, Florida State University; Robin H. Bogner, University of Connecticut; Ben J. Boyd, Monash University; Kenneth R. Brouwer, Qualyst Transporter Solutions; James Butler, GlaxoSmithKline; Stephen R. Byrn, Purdue University; Adeola O. Coker, University of the Incarnate Word; Duncan Craig, UCL School of Pharmacy; Martyn Davies, University of Nottingham; Yoshiharu Deguchi, Teikyo University; Jennifer Dressman, Goethe University; Mark T. Fisher, University of Kansas Medical Center; Kosalaram Goteti, Pfizer, Inc.; Henrik Gréen, Linköping University and National Board of Forensic Medicine; Margareta Hammarlund-Udenaes, Uppsala University; Ken-ichi Hosoya, University of Toyama; Ken-ichi Izutsu, National Institute of Health Sciences, Japan; Kevin C. Johnson, Intellipharm, LLC; David S. Jones, Queen’s University Belfast; Vitaliy V. Khutoryanskiy, University of Reading; Peter Kleinebudde, Heinrich-Heine-Universität; Janet G. Koe, JGIJ Consulting, LLC; Robert S. Langer, Massachusetts Institute of Technology; Thorsteinn Loftsson, University of Iceland; Michael B. Maurin, Maurin Healthcare Consulting; Mark McAllister, Pfizer, Inc.; S. Narasimha Murthy, University of Mississippi; Steven L. Nail, Baxter Medical Products; Ashwini Nangia, University of Hyderabad; Linda Narhi, Amgen, Inc.; Marino Nebuloni, University of Parma; Hanne Mørck Nielsen, University of Copenhagen; Takuo Ogihara, Takasaki University of Health and Welfare; Sumio Ohtsuki, Kumamoto University; Michael J. Pikal, University of Connecticut; Richard J. Prankerd, Monash University; Theodore Randolph, University of Colorado; Susan M. Reutzel-Edens, Eli Lilly and Company; Kevin G. Rice, University of Iowa; Naír Rodríguez-Hornedo, University of Michigan; Mark C. Rogge, Takeda Pharmaceutical Company; Amy S. Rosenberg, Center for Drug Evaluation and Research; Chandrahas Sahajwalla, Silver Spring, MD; Krishnan Sampathkumar, Macrogenics, Inc.; Abu T. M. Serajuddin, St. John’s University; Danny D. Shen, University of Washington; Teruna J. Siahaan, University of Kansas; Valentino J. Stella, University of Kansas; Audra L. Stinchcomb, University of Maryland; Robert G. Strickley, Gilead Sciences; Yun K. Tam, Sinoveda Canada Inc.; Dhiren R. Thakker, University of North Carolina; Susumu Uchiyama, Osaka University; Geert Verreck, Janssen Pharmaceuticals; David B. Volkin, University of Kansas; Adrian C. Williams, University of Reading; Gerhard Winter, LMU München; Hiroshi Yamazaki, Showa Pharmaceutical University; J. Axel Zeitler, University of Cambridge; Lucia Zema, Università degli Studi di Milano; and Gaylen M. Zentner, Comprehensive CMC Outsourcing, LLC.
      To read this article in full you will need to make a payment
      APhA Member Login
      APhA Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect